NASDAQ:OSA - Nasdaq - US50535E1082 - Common Stock - Currency: USD
0.47
-0.05 (-10.29%)
The current stock price of OSA is 0.47 USD. In the past month the price decreased by -29.09%. In the past year, price decreased by -90.8%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Prosomnus, Inc. is a medical technology company, which engages in the business of developing, manufacturing, and marketing precision intraoral medical devices. The company is headquartered in Pleasanton, California and currently employs 129 full-time employees. The company went IPO on 2021-06-15. The Company’s intraoral medical devices are engineered to track the treatment plan and anatomy of each patient. Its precision intraoral devices are Food and Drug Administration (FDA)-cleared, patented and covered by commercial medical insurance, Medicare, TRICARE and other Government-sponsored healthcare plans around the world, representing approximately 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide. The Company’s wholly owned subsidiaries include ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc.
PROSOMNUS INC
5675 Gibraltar Dr
Pleasanton CALIFORNIA US
Employees: 129
Company Website: https://prosomnus.com/
Phone: 18445375337
The current stock price of OSA is 0.47 USD. The price decreased by -10.29% in the last trading session.
The exchange symbol of PROSOMNUS INC is OSA and it is listed on the Nasdaq exchange.
OSA stock is listed on the Nasdaq exchange.
7 analysts have analysed OSA and the average price target is 2.55 USD. This implies a price increase of 442.55% is expected in the next year compared to the current price of 0.47. Check the PROSOMNUS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PROSOMNUS INC (OSA) has a market capitalization of 8.17M USD. This makes OSA a Nano Cap stock.
PROSOMNUS INC (OSA) currently has 129 employees.
PROSOMNUS INC (OSA) has a resistance level at 0.57. Check the full technical report for a detailed analysis of OSA support and resistance levels.
The Revenue of PROSOMNUS INC (OSA) is expected to grow by 41.66% in the next year. Check the estimates tab for more information on the OSA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OSA does not pay a dividend.
PROSOMNUS INC (OSA) will report earnings on 2024-05-10, after the market close.
PROSOMNUS INC (OSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
ChartMill assigns a fundamental rating of 1 / 10 to OSA. OSA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months OSA reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS decreased by -28.77% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -49.44% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 77% to OSA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -101.05% and a revenue growth 41.66% for OSA